Joshua Jennings
Stock Analyst at TD Cowen
(3.32)
# 983
Out of 5,152 analysts
82
Total ratings
46.75%
Success rate
4.33%
Average return
Main Sectors:
Stocks Rated by Joshua Jennings
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BFLY Butterfly Network | Maintains: Buy | $4.5 → $6 | $3.76 | +59.57% | 1 | Feb 27, 2026 | |
| PRCT PROCEPT BioRobotics | Maintains: Buy | $50 → $34 | $25.35 | +34.12% | 5 | Feb 26, 2026 | |
| BSX Boston Scientific | Maintains: Buy | $115 → $100 | $72.99 | +37.01% | 8 | Feb 5, 2026 | |
| JNJ Johnson & Johnson | Maintains: Buy | $222 → $250 | $239.63 | +4.33% | 2 | Jan 22, 2026 | |
| EW Edwards Lifesciences | Upgrades: Buy | $90 → $97 | $83.89 | +15.63% | 2 | Jan 9, 2026 | |
| OBIO Orchestra BioMed Holdings | Initiates: Buy | $15 | $4.49 | +234.08% | 1 | Dec 10, 2025 | |
| CBLL CeriBell | Maintains: Buy | $36 → $20 | $17.89 | +11.79% | 3 | Nov 5, 2025 | |
| SENS Senseonics Holdings | Maintains: Buy | $25 → $15 | $6.11 | +145.70% | 2 | Nov 5, 2025 | |
| DXCM DexCom | Maintains: Buy | $100 → $84 | $70.69 | +18.83% | 2 | Oct 31, 2025 | |
| HUMA Humacyte | Maintains: Buy | $5 → $3.5 | $1.09 | +221.10% | 3 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $6.33 | +136.97% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $264 → $324 | $240.94 | +34.47% | 1 | Jan 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $175 → $120 | $140.07 | -14.33% | 9 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $0.71 | +6,931.36% | 1 | Oct 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $143 → $119 | $93.45 | +27.34% | 1 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $55 → $60 | $34.00 | +76.47% | 2 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $83 → $80 | $80.07 | -0.09% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $135 → $45 | $3.44 | +1,210.04% | 3 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 | $18.60 | +115.05% | 4 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $365 → $400 | $370.50 | +7.96% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $60 | $71.36 | -15.92% | 4 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $52 → $34 | $22.63 | +50.24% | 2 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $18 | $7.49 | +140.32% | 3 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $25 | $17.45 | +43.27% | 1 | Dec 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $130 | $111.04 | +17.07% | 9 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $5 | $2.19 | +128.31% | 1 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $117 | $93.01 | +25.79% | 3 | May 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $12 | $12.57 | -4.53% | 1 | Sep 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $306 → $275 | $169.94 | +61.82% | 1 | Feb 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $28 → $28 | $10.07 | +173.09% | 3 | Sep 5, 2018 |
Butterfly Network
Feb 27, 2026
Maintains: Buy
Price Target: $4.5 → $6
Current: $3.76
Upside: +59.57%
PROCEPT BioRobotics
Feb 26, 2026
Maintains: Buy
Price Target: $50 → $34
Current: $25.35
Upside: +34.12%
Boston Scientific
Feb 5, 2026
Maintains: Buy
Price Target: $115 → $100
Current: $72.99
Upside: +37.01%
Johnson & Johnson
Jan 22, 2026
Maintains: Buy
Price Target: $222 → $250
Current: $239.63
Upside: +4.33%
Edwards Lifesciences
Jan 9, 2026
Upgrades: Buy
Price Target: $90 → $97
Current: $83.89
Upside: +15.63%
Orchestra BioMed Holdings
Dec 10, 2025
Initiates: Buy
Price Target: $15
Current: $4.49
Upside: +234.08%
CeriBell
Nov 5, 2025
Maintains: Buy
Price Target: $36 → $20
Current: $17.89
Upside: +11.79%
Senseonics Holdings
Nov 5, 2025
Maintains: Buy
Price Target: $25 → $15
Current: $6.11
Upside: +145.70%
DexCom
Oct 31, 2025
Maintains: Buy
Price Target: $100 → $84
Current: $70.69
Upside: +18.83%
Humacyte
Aug 12, 2025
Maintains: Buy
Price Target: $5 → $3.5
Current: $1.09
Upside: +221.10%
Jan 7, 2025
Initiates: Buy
Price Target: $15
Current: $6.33
Upside: +136.97%
Jan 3, 2025
Maintains: Buy
Price Target: $264 → $324
Current: $240.94
Upside: +34.47%
Nov 18, 2024
Maintains: Buy
Price Target: $175 → $120
Current: $140.07
Upside: -14.33%
Oct 2, 2024
Initiates: Buy
Price Target: $50
Current: $0.71
Upside: +6,931.36%
Sep 6, 2024
Maintains: Hold
Price Target: $143 → $119
Current: $93.45
Upside: +27.34%
Aug 27, 2024
Maintains: Buy
Price Target: $55 → $60
Current: $34.00
Upside: +76.47%
Aug 13, 2024
Maintains: Hold
Price Target: $83 → $80
Current: $80.07
Upside: -0.09%
Aug 8, 2024
Maintains: Buy
Price Target: $135 → $45
Current: $3.44
Upside: +1,210.04%
May 10, 2024
Downgrades: Hold
Price Target: $40
Current: $18.60
Upside: +115.05%
Apr 11, 2024
Maintains: Buy
Price Target: $365 → $400
Current: $370.50
Upside: +7.96%
Mar 12, 2024
Maintains: Outperform
Price Target: $50 → $60
Current: $71.36
Upside: -15.92%
Aug 4, 2023
Maintains: Outperform
Price Target: $52 → $34
Current: $22.63
Upside: +50.24%
May 11, 2023
Maintains: Outperform
Price Target: $14 → $18
Current: $7.49
Upside: +140.32%
Dec 30, 2022
Maintains: Outperform
Price Target: $6 → $25
Current: $17.45
Upside: +43.27%
Dec 13, 2022
Maintains: Outperform
Price Target: $130
Current: $111.04
Upside: +17.07%
Nov 11, 2022
Maintains: Outperform
Price Target: $7 → $5
Current: $2.19
Upside: +128.31%
May 27, 2022
Maintains: Outperform
Price Target: $125 → $117
Current: $93.01
Upside: +25.79%
Sep 3, 2020
Initiates: Outperform
Price Target: $12
Current: $12.57
Upside: -4.53%
Feb 7, 2020
Downgrades: Market Perform
Price Target: $306 → $275
Current: $169.94
Upside: +61.82%
Sep 5, 2018
Downgrades: Market Perform
Price Target: $28 → $28
Current: $10.07
Upside: +173.09%